CrisprCas9 Kit

Cas9 Protein and T7 gRNA SmartNuclease Synthesis Kit
CAS400A-KIT 1 kit (10 rxn)
EUR 1332

Abmgood Laboratories manufactures the crispr/cas9 kit reagents distributed by Genprice. The Crispr/Cas9 Kit reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact ABMgood. Other Crispr/Cas9 products are available in stock. Specificity: Crispr/Cas9 Category: Kit

Canine True insulin ELISA kit
96T
EUR 700
Description: ELISA

Mouse True insulin ELISA kit
96T
EUR 700
Description: ELISA

Rabbit True insulin ELISA kit
96T
EUR 700
Description: ELISA

Rat True insulin ELISA kit
96T
EUR 700
Description: ELISA

Bovine True insulin ELISA kit
96T
EUR 700
Description: ELISA

Mouse True insulin ELISA kit
192 tests
EUR 1524
Description: A competitive ELISA for quantitative measurement of Mouse True insulin in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Mouse True insulin ELISA kit
1 plate of 48 wells
EUR 624
Description: A competitive ELISA for quantitative measurement of Mouse True insulin in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Serum / Plasma information

KIT sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)
K1152305 3 x 1.0 ug
EUR 451.2

Kit sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse)
K4860905 3 x 1.0 ug
EUR 451.2

FCGR2A CRISPR/Cas9 Lentivirus (Integrating)
78537 500 µl x 2
EUR 795
Description: Fc Gamma Receptor 2A (also known as CD32A, Fc-gamma-RIIa, FcgRIIa) is a low affinity Fc receptor for immunoglobulin G, encoded by the FCGR2A gene. Fc Gamma Receptor 2A is a cell surface receptor that is expressed on a variety of immune cells such as macrophages and neutrophils. It is involved in phagocytosis and in the clearing of spent immune complexes from the circulation. A polymorphism in FCGR2A has been associated with increased risks of nephritis and lupus.The FCGR2A CRISPR/Cas9 Lentiviruses are replication incompetent, HIV-based VSV-G pseudo-typed lentiviral particles that are ready to transduce into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 5 sgRNA (single guide RNA) targeting human FCGR2A.

Mouse Anti- CRISPR/Cas9 [7A9-3A3]
MBS375383-002mg 0.02mg
EUR 335

Mouse Anti- CRISPR/Cas9 [7A9-3A3]
MBS375383-005mg 0.05mg
EUR 485

Mouse Anti- CRISPR/Cas9 [7A9-3A3]
MBS375383-01mg 0.1mg
EUR 560

Mouse Anti- CRISPR/Cas9 [7A9-3A3]
MBS375383-5x01mg 5x0.1mg
EUR 2305

PD-1 CRISPR/Cas9 Lentivirus (Integrating)
78052 500 µl x 2
EUR 820
Description: The binding of Programmed Cell Death Protein 1 (PD-1), a receptor expressed on activated T-cells, to its ligands, PD-L1 and PD-L2, negatively regulates immune responses. PD-1 ligands are found on most cancers, and the PD-1:PD-L1/2 interaction inhibits T-cell activity and enables cancer cells to escape immune surveillance. The PD-1:PD-L1/2 pathway is also involved in regulating autoimmune responses, making these proteins promising therapeutic targets for a number of cancers, as well as multiple sclerosis, arthritis, lupus, and type I diabetes._x000D_
The PD-1 CRISPR Lentiviruses are replication incompetent, HIV-based VSV-G pseudo-typed lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 4 sgRNA (single guide RNA) targeting human PD-1 (Programmed Cell Death 1, PDCD1, CD279, GenBank Accession #NM_005018) driven by a U6 promoter (Figures 1 and 2)._x000D_
The integrating lentivirus integrates randomly into the cell's genome to express both the Cas9 and sgRNA. Puromycin selection increases the knockout efficiency by forcing high expression levels of both Cas9 and the sgRNA, and can be used with the integrating lentivirus to quickly and easily achieve high knockdown efficiencies in a cell pool. Efficiencies also depend on the cell type and the gene of interest._x000D_ _x000D_

CRISPR Cas9 SP Rabbit Polyclonal Antibody
E10G23119 100 μl
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

Kit sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1)
K6939006 1.0 ug DNA
EUR 200.4

Kit sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2)
K6939007 1.0 ug DNA
EUR 200.4

Kit sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3)
K6939008 1.0 ug DNA
EUR 200.4

PD-L1 CRISPR/Cas9 Lentivirus (Integrating)
78057 500 µl x 2
EUR 795
Description: The binding of Programmed Cell Death Protein 1 (PD-1), a receptor expressed on activated T-cells, to its ligands, PD-L1 and PD-L2, negatively regulates immune responses. The PD-1 ligands are found on most cancers, and the PD-1:PD-L1/2 interaction inhibits T-cell activity and allows cancer cells to escape immune surveillance. The PD-1:PD-L1/2 pathway is also involved in regulating autoimmune responses, making these proteins promising therapeutic targets for a number of cancers, as well as multiple sclerosis, arthritis, lupus, and type I diabetes._x000D_The PD-L1 CRISPR Lentiviruses are replication incompetent, HIV-based, VSV-G pseudo-typed lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 4 sgRNA (single guide RNA) targeting human PD-L1 (Programmed Cell Death 1 Ligand 1, CD274, B7 homolog 1 (B7-H1), GenBank accession #NM_021893) driven by a U6 promoter (Figures 1 and 2)._x000D_The integrating lentivirus integrates randomly into the cell's genome to express both the Cas9 and sgRNA. Puromycin selection increases the knockout efficiency by forcing high expression levels of both Cas9 and the sgRNA, and can be used with the integrating lentivirus to quickly and easily achieve high knockdown efficiencies in a cell pool. Efficiencies also depend on the cell type and the gene of interest._x000D_

CRISPR/Cas9 (SaCas9) Monoclonal Antibody [6H4]
A-9001
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 µg
  • 10 ug
  • 50 ug
  • 100 ug

KIT sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1)
K1152306 1.0 ug DNA
EUR 200.4

KIT sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2)
K1152307 1.0 ug DNA
EUR 200.4

KIT sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3)
K1152308 1.0 ug DNA
EUR 200.4